BANK VONTOBEL/CALL/IDORSIA/22/0.25/21.06.24

BANK VONTOBEL/CALL/IDORSIA/22/0.25/21.06.24 Share Price

Warrant

WIDA9V

CH1236780685

Market Closed - Swiss Exchange 16:20:00 06/12/2023 GMT
0.05 ^CHF	+35.14%

3 months	+85.19%
6 months	-51.92%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart BANK VONTOBEL/CALL/IDORSIA/22/0.25/21.06.24

Latest news about IDORSIA LTD

Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call	05-14	GL
Idorsia Secures Bondholders' Approval for Amendment to Terms of Outstanding Convertible Bonds	05-07	MT
Bondholders approve amended terms of the 2024 convertible bonds	05-06	GL
Idorsia Boosts Consent Fee Offer to 2024 Convertible Bond	05-02	MT

More news

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	Vontobel
	WIDA9V
ISIN	CH1236780685
Date issued	18/01/2023
Strike	22 CHF
Maturity	21/06/2024 (32 Days)
Parity	4 : 1
Emission price	0.52 CHF
Emission volume	N/A
Settlement	physique
Currency	CHF

Technical Indicators

Highest since issue	0.62 CHF
Lowest since issue	0.02 CHF
Delta	0x
Omega	0.000000
Premium	0x
Gearing	0x
Moneyness	0.0982
Difference Strike	19.78 CHF
Difference Strike %	+89.91%
Intrinsic value	0.000000

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company